Market
How many new diagnostic products will Quanterix and Akoya launch post-merger by end of 2025?
2
Resolution / Starting Odds
0 • 25%
1 • 25%
2-3 • 25%
4 or more • 25%
Official product announcements or company reports
Story
Quanterix to Acquire Akoya Biosciences in All-Stock Deal for First Integrated Solution in Ultra-Sensitive Biomarker Detection
Jan 10, 2025, 11:37 AM
Quanterix Corporation has reached an agreement to acquire Akoya Biosciences in an all-stock transaction. This merger aims to create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers, enhancing capabilities in disease detection at various stages. Both companies are recognized for their contributions to life sciences, with Quanterix focusing on advanced biomarker detection technologies and Akoya specializing in spatial biology solutions. The deal is expected to combine their strengths and improve diagnostic capabilities in the healthcare sector.
View original story
Similar markets
No new partnerships • 25%
1 new partnership • 25%
More than 3 new partnerships • 25%
2 to 3 new partnerships • 25%
1-2 • 25%
3-4 • 25%
None • 25%
5 or more • 25%
3 new species • 25%
More than 3 new species • 25%
1 new species • 25%
2 new species • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
Focus on cancer treatments • 25%
Focus on other areas • 25%
Focus on both equally • 25%
Focus on genetic engineering • 25%
Successful acquisition of Sage Therapeutics • 25%
Successful acquisition of another biotech • 25%
No acquisitions completed • 25%
Multiple acquisitions completed • 25%
Yes • 50%
No • 50%
No significant contribution • 25%
Contributes less than 2% to revenue growth • 25%
Contributes more than 5% to revenue growth • 25%
Contributes 2-5% to revenue growth • 25%
